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We briefly review the surgical approaches to medullary thyroid carcinoma associated with multiple endocrine
neoplasia type 2 (medullary thyroid carcinoma/multiple endocrine neoplasia type 2). The recommended surgical
approaches are usually based on the age of the affected carrier/patient, tumor staging and the specific rearranged
during transfection codon mutation. We have focused mainly on young children with no apparent disease who are
carrying a germline rearranged during transfection mutation. Successful management of medullary thyroid
carcinoma in these cases depends on early diagnosis and treatment. Total thyroidectomy should be performed
before 6 months of age in infants carrying the rearranged during transfection 918 codon mutation, by the age of 3
years in rearranged during transfection 634 mutation carriers, at 5 years of age in carriers with level 3 risk
rearranged during transfection mutations, and by the age of 10 years in level 4 risk rearranged during transfection
mutations. Patients with thyroid tumor .5 mm detected by ultrasound, and basal calcitonin levels .40 pg/ml,
frequently have cervical and upper mediastinal lymph node metastasis. In the latter patients, total thyroidectomy
should be complemented by extensive lymph node dissection. Also, we briefly review our data from a large familial
medullary thyroid carcinoma genealogy harboring a germline rearranged during transfection Cys620Arg mutation.
All 14 screened carriers of the rearranged during transfection Cys620Arg mutation who underwent total
thyroidectomy before the age of 12 years presented persistently undetectable serum levels of calcitonin (,2 pg/ml)
during the follow-up period of 2–6 years. Although it is recommended that preventive total thyroidectomy in
rearranged during transfection codon 620 mutation carriers is performed before the age of 5 years, in this particular
family the surgical intervention performed before the age of 12 years led to an apparent biochemical cure.
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INTRODUCTION
In the era of genomic medicine, multiple endocrine
neoplasia (MEN) represents a model paradigm of the strong
impact of genetic testing on clinical practice (1–4). An
example of this is the impressive impact of mutation
analysis of the RET proto-oncogene, which leads to MEN
type 2 (MEN2A), on the day-to-day activity of clinicians,
endocrinologists, neck surgeons, and urologists (5,6). As a
result of this, RET germline mutation carriers detected at an
early age are able to undergo preventive total thyroidect-
omy (TT), which has a high ‘‘cure’’ rate. This surgical
approach may ultimately lead to prevention of highly
malignant medullary thyroid carcinoma (MTC), either in
its inherited or sporadic (S-MTC) form (5–8).
The well-defined genetic origin of the condition and the
possibility of prophylactic surgical treatment of MTC make
it a model for early diagnosis, genetic counseling, surgical
prevention and therapy, as well as cancer research (9,10).
This uncommon tumor has its origin in the thyroid C-cells
and accounts for 4–5% of all thyroid cancer tumors in the
USA, and it is the main cause of death in MEN2 patients
(11,12). MTC may occur as a dominant inherited condition
caused by a germline mutation in the RET gene in 20–30% of
cases of MEN2, although S-MTC is the more prevalent form
of the disease.
MTC presents different levels of aggressiveness: (a) it is
extremely aggressive and usually occurs during the first
year of life in MEN2B (MTC, hyperparathyroidism, pheo-
chromocytoma, and mucosal neuromas); (b) it is highly
aggressive in MEN2A (MTC, hyperparathyroidism, and
pheochromocytoma) mostly in cases harboring a RET 634
codon mutation; and (c) it is often moderately aggressive in
familial MTC (FMTC), as well as in S-MTC (13). Therefore,
the behavior of MTC in MEN2 may present extreme
variations, ranging from an indolent MTC, as frequently
seen in cases harboring intracellular ‘‘weak’’ mutations, to
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highly aggressive MTC in cases with RET mutations in
codon 634 and mainly in codon 918 (5,14,15).
Lymph node metastasis in the neck and upper medias-
tinum is a frequent finding in MTC cases that are diagnosed
late, and metastases are present in about 70% of MTC
patients who have a palpable thyroid nodule (.1.0 cm
diameter). At this stage of the disease, biochemical ‘‘cure’’
rates drop to 30% or less (16,17). Thus, in RET mutation
carriers, all efforts should be focused on early diagnosis and
surgical treatment of MTC (5,14,15). The only effective
treatment for this condition is TT, although several drugs
acting on the RET receptor protein kinase have been tested
in clinical trials (18).
Calcitonin measurements
Calcitonin (Ct) is produced by thyroid C-cells and is the
tumor marker for MTC. Currently, basal serum Ct measure-
ments and the calcium-stimulated Ct test have been mainly
used during the post-surgical follow-up of cases of inherited
MTC (5,17). The calcium-stimulated Ct test may be used to
predict MTC in patients who present without a thyroid
nodule at ultrasound and who have repeatedly normal basal
Ct values (males, ,8.5 pg/ml; females, ,5.0 pg/ml). The
higher risk of MTC in cases with abnormally high Ct levels
after a calcium-stimulation test could further support an
indication for prophylactic TT, possibly with dissection of
the central compartment of the neck. However, some
specialists argue that calcium-stimulated Ct testing is rarely
needed in the diagnosis or follow-up of MTC, because new
Ct assays have high sensitivity and specificity, and detection
values are as low as 1–2 pg/ml (15).
Conversely, Ct measurements may be highly helpful in
the diagnosis of S-MTC cases, which are often diagnosed
late. In this context, routine Ct measurements in patients
with thyroid nodules may contribute to an earlier diagnosis
of MTC, although the prevalence of MTC in thyroid nodules
is about 1.0% (19,20).
Genetic testing
Genetic RET testing should be offered to all patients with
MTC (6), since between 1% and 7% of apparently sporadic
MTC cases harbor a germline RET mutation, and thus need
to be reclassified as inherited cases. Also, genetic RET
testing should be offered to all at-risk (50% risk) first-degree
relatives of patients with familial MTC, in order to disclose
potential carriers with positive mutations (1,5). Further to
this, genetic testing should be offered to all cases with
phaeochromocytoma, and possibly to patients with hyper-
parathyroidism who are younger than 30 years of age (5,21).
In at-risk relatives, genetic testing for MTC predisposition
should be performed at a very early age, as prophylactic
surgical intervention is able to prevent MTC in the vast
majority, but not all, of the RET-positive mutation carriers
who are below the age of 3–5 years (10).
Genetic RET testing is usually based on mutation analysis
of seven hot-spot exons: 8, 10, 11, 13, 14, 15, and 16. It allows
a genetic diagnosis at the pre-neoplastic early stage of MTC,
which corresponds to thyroid C-cell hyperplasia (5,15).
Surgical approach
Our main aim is to focus on recommended surgical
approaches in young children carrying a germline RET
mutation.
Recommended age for prophylactic thyroid surgery. The
age at which TT in RET-positive mutation carriers is
performed plays a crucial role in the success of MTC
treatment. The recommended ages for TT in MEN2 are
presently well defined and they are based on the strong
genotype–phenotype correlation in MEN2 (1,5,15). Thus,
surgery depends basically on the RET codon mutation
involved, although the behavior of the disease in a specific
family should also be considered in some cases.
At the Seventh International Workshop on MEN at the
National Institutes of Health (NIH) (5), a classification of the
risk of MTC was established based on the different degrees
of MTC aggressiveness, which in turn depend directly on
the codon in which the germline RET mutation has
occurred. Briefly, this consensus recommended that carriers
of mutations in extracellular RET codons, such as codons
634, 620, 618, and 609, should be operated on before the age
of 5 years. Individuals carrying mutations in intracellular
RET codons, such as codon 804, should undergo TT before
the age of 10 years. Patients carrying some specific RET
mutations, such as those in codons 790 and 791, may have
the surgery postponed, and be observed under a strict
follow-up. Carriers with a RET 918 mutation, which leads to
MEN2B, should be operated on by 6 months of age. The
purpose of this classification system was to offer a guideline
to clinical endocrinologists and neck surgeons.
Recently, the American Thyroid Association (ATA)
consensus on MTC added new recommendations (15).
Thus, individuals carrying the highly aggressive germline
RET mutations in codon 634 should undergo preventive
thyroid surgery before 5 years of age, possibly around 3
years of age, as MTC has been reported at ages as low as 3
years in RET 634 codon mutation carriers (10).
Several guidelines for the diagnosis and management of S-
MTC and MTC/MEN2 have been published by different
medical authorities such as the International MEN2 Con-
sortium (1), the NIH Workshop on MEN (5), the American
Society of Clinical Oncology (ASCO) (22), the ATA (MTC
Clinical Guidelines) (15), and the Brazilian Guidelines-MTC
(23), among others. The recommendations are broadly
similar, although small variations may be present.
General comments. Ideally, all surgical thyroid inter-
vention in MTC/MEN2 cases should be preventive.
However, in clinical practice, surgical interventions in
MTC may vary from prophylactic to palliative approaches
depending on the age at the MTC diagnosis and treatment,
the disease stage and the RET codon mutation.
Also, as it is mandatory in all surgical thyroid interven-
tion, a careful neck dissection is needed to avoid parathyr-
oid function damage, which may ultimately lead to
permanent hypoparathyroidism. Accordingly, special atten-
tion is necessary to protect the vascular supply of the
parathyroid glands. Also, this would decrease the chance of
cervical nerve lesion, which may lead to transient or
permanent nerve palsy. It is worth noting that possible
thyroid remnants left behind with thyroid C-cells during a
TT procedure, such as remnants in the posterior thyroid
capsule, may lead to persistent MTC, and may increase the
chance for recurrent disease (Tavares et al., unpublished
observations).
TT associated with removal of cervical and mediastinal
lymph node metastases should be performed by skilled
surgeons in tertiary centers with expertise in the manage-
ment of MTC cases.
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Previous investigation for pheochromocytoma is manda-
tory to avoid the potential risk of adrenal crisis during
surgery of MTC, since pheochromocytoma usually occurs in
50% of MEN2A cases (5). Also, hyperparathyroidism needs
to be investigated, since it affects 20–30% of MEN2A
patients.
Prophylactic treatment. Familial genetic screening of
the RET proto-oncogene frequently allows planned
prophylactic surgery in MEN2 (15).
Total thyroidectomy only. TT has a minimal morbidity.
It is recommended for most children aged 3–5 years with
RET-positive mutated MEN2A, and even beyond this age in
those presenting with normal basal serum Ct (,10 pg/ml),
no thyroid nodule (or nodules ,5 mm), or lymph node
metastasis in either side of the neck detected by ultrasound.
TT involves the excision of all thyroid tissue, including the
superior pole, isthmus, pyramidal remnants, posterior
capsule, tubercle of Zuckerkandl, and thyrothymic thyroid
rests (15).
In MEN2B, TT is recommended for children younger than
6 months of age with no evidence of disease or thyroid
nodule .5 mm and no lymph node metastasis. However,
MEN2B cases may present lymph node metastasis at a very
young age. Thus, when TT is performed after the first year
of life, it is usually associated with cervical lymph node
dissection.
In patients with hereditary MTC, disease-free survival is
best predicted by tumor, node, metastases (TNM) staging
and a preoperative basal Ct level below 30 pg/ml. Basal Ct,
class D genotype, and age constitute the key determinants in
deciding the timing of preoperative surgery (24).
TT and dissection of the central compartment of the neck
(levels VI and VII). The central neck compartment lies in
and near the median sagittal plane of the neck and
comprises lymph nodes in the pre- and paratracheal area,
and precricoid (Delphian) and perithyroidal areas. The
central neck is divided into sublevels (25,26) that comprise
the following: the prelaryngeal lymph nodes, between the
hyoid bone and the superior margin of isthmus of the
thyroid gland; the region lateral to the right and left
recurrent laryngeal nerve; the pretracheal sublevel,
anterior to the trachea from the inferior pole of the thyroid
gland, and above the brachiocephalic vein and aortic arch,
which includes level VII of the neck. There are few
anatomical landmarks and limited appropriate functional
studies to individualize the group of lymph nodes located
between the recurrent laryngeal nerves below the inferior
pole of the thyroid gland and above the brachiocephalic
vein and aortic arch (Figure 1). Surgical access to level VII
without splitting the manubrium sternum is laborious, as it
is a narrow cavity containing important vessels and other
anatomical structures and also some parathyroid glands
(26).
We start the central neck dissection by identifying the left
common carotid artery at the level of the hyoid bone. It
proceeds caudally on the anteromedial rim of the carotid
artery until it reaches the superior border of the left
innominate vein. From this point on, dissection goes
horizontally toward the right side following the superior
border of the vein, until it comes to the innominate artery.
Dissection follows cranially in the anterior wall of the
brachiocephalic and right carotid arteries and finishes at the
level of the hyoid bone at the right side of the neck. Lymph
nodes are removed en bloc in the level of the prevertebral
fascia, with partial resection of the upper part of the thymus.
Recurrent laryngeal nerves and parathyroid glands have
been identified previously during TT, and these should be
preserved.
TT associated with elective level VI central neck compart-
ment dissection is recommended in MEN2B cases harboring
the RET 918 mutation presenting with Ct .40 pg/ml, or
evidence of lymph node metastasis by ultrasound, even
when TT is to be performed during the first year of life. TT
associated with level VI central neck compartment dissec-
tion is also recommended in MEN2A/FMTC cases before
the age of 5 years with Ct .40 pg/ml or there is evidence of
lymph node metastasis.
TT complemented by prophylactic dissection of the
central neck may potentially avoid the risk of reoperation
of this neck compartment (5,15). This procedure is re-
commended for most RET-positive carriers older than 5
years who have a thyroid nodule ,5 mm observed by
ultrasound, but with Ct levels .40 pg/ml. The selection of
patients to avoid dissection of the central neck is based on
the increased risk for postsurgical hypoparathyroidism, a
complication with harmful long-term consequences in
children. Thus, the surgeon must pay special attention to
parathyroid glands and parathyroid vasculature during
central neck intervention.
Lateral neck dissection. Complimentary dissection of the
lateral neck is performed when jugulo-carotideal lymph
node metastases are identified by neck ultrasound. Lymph
nodes with a diameter .1.0 cm and round in shape are
suspicious and must be investigated for MTC metastasis by
Figure 1 - Sublevels of the central compartment of the neck. Spaces of the central compartment of the neck: prelaryngeal (1); lateral to
the recurrent laryngeal nerves on the right (2) and left (3) sides; pretracheal, between the recurrent laryngeal nerves (4).
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a performing cytology. It is important to emphasize that
lymph nodes with diameters ,1.0 cm may already have
minimal MTC metastases and cytological accuracy may be
not sufficiently high to detect these (8). Thus, a negative
cytology result should be followed by immunocytoche-
mistry for Ct and measurement of Ct levels in the washout
obtained using a fine needle aspiration biopsy.
Standard modified neck dissection preserving the sterno-
cleidomastoid muscle, jugular vein, and accessory nerve is
the best approach if there has been no previous neck
dissection. Elective dissection of the lateral compartment of
the neck is not indicated for MTC, unless follow-up is not
affordable. The low cure rate obtained with the extended
neck procedure is attributed to distant metastases.
Moreover, dissection of the lateral neck can be safely
performed a second time, if necessary.
Surgery for advanced disease. In MTC with a palpable
thyroid nodule .1.0 cm, central compartment, bilateral
and/or contralateral lymph node metastases are present in
up to 50–70% of cases (5). In most cases, TT followed by
dissection of central and both lateral neck compartments are
indicated. This procedure frequently takes a long time and
should be carried out carefully.
Thus, the decision to perform routine, extensive neck
lymph node dissection should be taken ideally after
confirmation of lymph node disease.
It is worthwhile mentioning that thyroid surgery is the
only current potentially curative therapeutic method for
MTC, although new drugs acting upon the RET protein
kinase receptor have been actively investigated (18).
Persistent and recurrent disease. Persistent or recurrent
MTC disease has been reported in up to 2–10% of young
patients after prophylactic TT, mostly in cases that had
operations after the ages of 8–13 years (12,27,28). In
agreement with this, there was no persistent or recurrent
MTC in a series of 50 children who underwent prophylactic
TT and central neck dissection before the age 8 years (27).
In an MTC series, tumors up to 5 mm were found in
seven of eight children, aged from 3 to 13 years, with a RET
634 codon mutation. After TT, a 3-year-old boy developed
hypoparathyroidism, a condition that that requires ongoing
calcium intake and also treatment with calcitriol; this
condition has also occurred in 30% of our adult MTC/
MEN2 patients after TT (Tavares et al., unpublished data).
Documented loco-regional recurrences can be treated by
reoperation of the central neck compartment and/or
selective neck dissection of the compromised lateral neck
lymph node echelons. Selective dissection is preferred to
extensive neck lymph node dissection, based on the high
probability that there are distant metastases in these cases,
and these render elective lymph node resection ineffective.
Isolated distant metastasis can be treated by surgery, and
radiation therapy and chemotherapy are used as palliative
measures. New drugs targeting the RET tyrosine kinase
receptor are in phase III clinical trials, and they have shown
good initial results (18).
Remission. There was no persistent or recurrent MTC in
a series of 50 children when they underwent prophylactic
thyroidectomy and central neck dissection before age 8
years (27). In a large series, Pelizzo et al. reported that all
patients undergoing TT at stages I and II were totally cured
(13). Also, in a family with FMTC resulting from the
Cys620Arg mutation, all patients undergoing TT below or at
12 years of age were cured biochemically (28). In family
members, it was shown that the chance of achieving a
biochemical cure in MTC is clearly dependent on the size of
the primary tumor.
Conversely, in one series of children with MEN2A and
FMTC who underwent prophylactic TT at age 4 years or
over, 11% experienced biochemical persistence or recur-
rence, and all of them were operated on at age 13 years or
above (12).
MTC diagnosed during thyroid surgery. TT is adequate
when MTC with a diameter ,5 mm is identified by frozen
section during surgery for a thyroid nodule. Central neck
dissection and examination of both lateral compartments of
the neck are necessary only if a positive lymph node is
detected. Lymph nodes .1 cm diameter, round in shape
and/or with a hard consistency are considered suspicious,
and must be excised and subjected to frozen section. Neck
dissection of levels II–V is mandatory in the side of the neck
with the positive lymph node. Lateral neck dissection is
indicated only for disease that has been detected. Although
comprehensive modified neck dissection of levels II–V is the
best treatment, selective dissection of the compromised level
may be considered for these patients. Elective dissection is
performed for MTC with a diameter .5 mm. In an attempt
to detect S-MTC or the index cases of MTC/MEN2 families
before surgery, the European Thyroid Association (ETA)
recommends that serum Ct should be routinely measured in
patients with thyroid nodules and clinical risk factors for
MTC (20). This procedure can benefit some people, as they
are able to better plan their surgery.
MTC diagnosed after thyroid surgery. In approximately
10–15% of cases of MTC, diagnosis is obtained by
pathological analysis after thyroidectomy for a thyroid
nodule (29). Since neck dissection is performed for positive
or suspicious lymph nodes, and also in well-differentiated
thyroid carcinomas, reoperation should not be the first step
considered in this difficult situation. Investigation should
begin with serum basal Ct level, neck ultrasound, and
analysis of RET proto-oncogene mutation. A normal Ct level
indicates that there is a very low chance of residual MTC,
and no other treatment is necessary. Standard follow-up is
sufficient in these cases.
Elevated postsurgical basal Ct levels indicate persistent
disease (15), and there is a trend for Ct levels to correlate
with disease stages (17). Tiny thyroid tissue amounts left
behind, most frequently undetectable, can result in Ct levels
,40 pg/ml. Ct levels .400 pg/ml probably indicate distant
metastases (15).
A diligent search for metastases in the neck, mediastinum,
bones, lung, and liver is accomplished by ultrasound and
computed tomography (CT) of these segments. Suspicious
nodules should be further examined by ultrasound or CT-
guided fine needle aspiration biopsy with cytological study.
Immunocytochemistry analysis for Ct, and Ct measure-
ments in the washout, are the next steps to be considered in
cases with a negative cytology sample. Patients whose
examinations are normal are carefully followed up with
basal Ct and neck ultrasound. If a rise in Ct is noticed, a
further CT is helpful to establish the disease staging (15).
Parathyroid glands. High priority must be given to
preserving parathyroid function (15). Normal parathyroid
glands should be left in situ with an adequate vascular
pedicle whenever possible. Accidentally resected or
devascularized normal parathyroid glands must be
immediately autografted in the neck of MTC patients who
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are RET negative, and in MEN2B and FMTC patients. In
contrast, in patients with MEN2A, the parathyroid glands
should be routinely autografted to a heterotopic site in the
neck or forearm. Furthermore, the location for implantation
of the excised parathyroid tissue is determined by the type
of RET mutation present. Patients with a strong family
history of HPT or those harboring a RET mutation
associated with an increased risk of HPT (i.e., at codon
634) should have the parathyroid implant placed in the
forearm. If the MTC patient has MEN2B, FMTC, or a
mutation with a low risk of HPT, the graft can be placed in
the sternocleidomastoid muscle (23).
Surgical neck exploration to remove a parathyroid
adenoma is indicated only after secure localization of the
enlarged gland. Normal glands are left in situ. Excision of
the four glands is indicated only if all glands are clearly
abnormal.
Prophylactic treatment of HPT is not usually performed
in all academic centers, as HPT is absent in cases of FMTC
and MEN2B, although it occurs in 20–30% of MEN2A
patients. Moreover, HPT associated with MEN2A fre-
quently presents as a single parathyroid adenoma that, in
many instances, can be localized by image studies such as
ultrasound and/or sestamibi scintigraphy (5).
Follow-up. Long-term postoperative follow-up is
recommended in MTC, either to confirm biochemical cure
or monitor the patient for persistent or recurrent MTC
disease.
Due to the high sensitivity and specificity of the methods
for Ct measurements, persistently undetectable basal levels
of Ct (,2 pg/ml) indicate absence or remission of MTC,
whereas detectable Ct levels usually indicate the presence of
MTC disease.
However, up to 5% of MTC cases with undetectable basal
Ct levels who undergo TT may show abnormally high
calcium-stimulated Ct values (.80 pg/ml). These latter
cases cannot be considered to be cured, and they should be
followed up carefully. Accordingly, recurrence may occa-
sionally occur 5–7 years after the initial surgical treatment,
even though there was a prolonged period in which Ct
remained undetectable (,2 pg/ml) (5).
During follow-up, a neck ultrasound can identify suspi-
cious lymph node metastases. A negative ultrasound
eliminates the risk of neck metastasis, and indicates that a
search for distant metastases may be needed. It is worth-
while pointing out that several conditions other than MTC
may be associated with increased Ct levels, and these
conditions should be ruled out (19).
As there is a correlation between basal Ct levels and MTC
disease staging, chest and abdominal CT are indicated to
search for distant metastases in cases with basal Ct levels
.400 pg/ml. MTC disease may be frequently difficult to
locate, and all suspicious lymph nodes should be routinely
sampled by fine-needle aspiration biopsy followed by
immunocytochemistry analysis for Ct. The complete set of
recommended investigations is given in the ATA guidelines
(15).
Experience from an academic center
Briefly, our long-term accumulated experience with
MTC/MEN2 patients comes from a single academic center:
the Hospital das Clı´nicas, University of Sa˜o Paulo
(7,8,16,19,23,28,30–36). The medical and scientific collabora-
tion of the head and neck team together with the Endocrine
Genetics Unit in the Department of Endocrinology began in
the early 1990s (30,31) and has continued up to the present
day (28,36). Here, we would like to briefly mention our
observation in a large family with FMTC from the north-east
area Brazil, with more than 35 affected individuals harbor-
ing the germline heterozygous RET Cys620Arg mutation. So
far, in this family, we have obtained persistent biochemical
remission (Ct ,2 pg/ml) in 14 RET-positive carriers who
underwent TT before or at 12 years of age, although RET 620
codon mutation carriers should be ideally undergo TT by
the age of 5 years (5,15). Partial data obtained from this
family have been published previously, as part of an
international consortium on RET exon 10 mutation (28).
In conclusion, we have briefly reviewed some specific
aspects of the surgical approaches to MTC, mostly those
recommended for young asymptomatic children carrying a
germline RET mutation.
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